NASDAQ:JBIO Jade Biosciences (JBIO) Stock Price, News & Analysis $7.71 +0.09 (+1.18%) As of 02:38 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Jade Biosciences Stock (NASDAQ:JBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Jade Biosciences alerts:Sign Up Key Stats Today's Range$7.51▼$7.9850-Day Range$6.77▼$11.1452-Week Range$6.57▼$105.00Volume19,771 shsAverage Volume161,143 shsMarket Capitalization$251.58 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingBuy Company Overview Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Read More Jade Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreJBIO MarketRank™: Jade Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 567th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingJade Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageJade Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Jade Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Jade Biosciences is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jade Biosciences is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJade Biosciences has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for JBIO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJade Biosciences does not currently pay a dividend.Dividend GrowthJade Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for JBIO. News and Social Media3.2 / 5News Sentiment0.77 News SentimentJade Biosciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Jade Biosciences this week, compared to 2 articles on an average week.Search Interest3 people have searched for JBIO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Jade Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jade Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders24.90% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Jade Biosciences' insider trading history. Receive JBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JBIO Stock News HeadlinesJade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being ...September 2 at 7:58 PM | finance.yahoo.comJade Biosciences Initiates Phase 1 Trial for JADE101 as Potential Disease-Modifying Treatment for IgANSeptember 2 at 7:30 AM | quiverquant.comQ"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That's why we've rushed to update our book "Crypto Revolution" – to show you exactly how to position yourself for this historic opportunity.September 3 at 2:00 AM | Crypto 101 Media (Ad)Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA NephropathySeptember 2 at 7:00 AM | globenewswire.comJade Biosciences Reports Q2 2025 Financial ResultsAugust 26, 2025 | tipranks.comJade Biosciences, Inc. to Participate in Key Biotechnology Conferences in September 2025August 25, 2025 | quiverquant.comQJade Biosciences to Participate in Upcoming ConferencesAugust 25, 2025 | globenewswire.comJade Biosciences Posts Wider Loss in Q2August 14, 2025 | theglobeandmail.comSee More Headlines JBIO Stock Analysis - Frequently Asked Questions How have JBIO shares performed this year? Jade Biosciences' stock was trading at $7.06 at the beginning of the year. Since then, JBIO stock has increased by 9.2% and is now trading at $7.71. How were Jade Biosciences' earnings last quarter? Jade Biosciences, Inc. (NASDAQ:JBIO) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.43. Who are Jade Biosciences' major shareholders? Jade Biosciences' top institutional investors include Frazier Life Sciences Management L.P. (210.97%), Versant Venture Management LLC (181.43%), Soleus Capital Management L.P. (94.85%) and Geode Capital Management LLC (80.43%). How do I buy shares of Jade Biosciences? Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2025Today9/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JBIO Previous SymbolNASDAQ:JBIO CIK1798749 WebN/A Phone(617) 443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Jade Biosciences$16.00 High Price Target$18.00 Low Price Target$14.00 Potential Upside/Downside+110.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($30.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.96% Return on Assets-47.65% Debt Debt-to-Equity RatioN/A Current Ratio10.31 Quick Ratio10.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.18 per share Price / Book1.23Miscellaneous Outstanding Shares32,630,000Free Float24,503,000Market Cap$248.64 million OptionableN/A Beta1.04 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:JBIO) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jade Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jade Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.